This reactive astrocyte phenotype is also observed in active MS lesions, reflected by co‐expression of C3 and GFAP, and to a lesser extent also in chronic active and inactive lesions (Liddelow et al., 2017), suggesting this phenotype is mostly present during earlier phases of lesion pathology. This evidence concerns the gene GFAP and myeloid sarcoma.